Article 26 Apr 2024 DOJ Files False Claims Act Complaint Against Regeneron, Alleging Fraudulent Eylea Drug Pricing United States Healthcare
Article 11 Mar 2024 Post-Trial Updates On Regeneron V. Mylan (Aflibercept) BPCIA Litigation United States IP
Article 02 Sep 2022 Amgen Announces Positive Top-Line Results From Phase 3 Study Of Eculizumab Biosimilar United States Healthcare